Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Blood (2018) 132 (9): 948–961.

https://doi.org/10.1182/blood-2018-02-832253

Published: 2018

Includes: Supplemental data

Journal Articles

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

Naranie Shanmuganathan, MBBS, FRACP, FRCPA, Susan Branford, PhD FFSc (RCPA), Jodi Braley, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1890.

https://doi.org/10.1182/blood.V128.22.1890.1890

Published: 2016

Journal Articles

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Blood (2015) 125 (6): 915–923.

https://doi.org/10.1182/blood-2014-07-590315

Published: 2015

Includes: Supplemental data

Journal Articles

Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint

Susan Branford, PhD, David M Ross, MBBS, PhD FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Jodi Braley, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4561.

https://doi.org/10.1182/blood.V124.21.4561.4561

Published: 2014

Journal Articles

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Susan Branford, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Wendy T Parker, PhD, Jodi Braley, John F Seymour, MBBS, FRACP, PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 816.

https://doi.org/10.1182/blood.V124.21.816.816

Published: 2014

NARROW

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Email alerts

ASH Publications

American Society of Hematology

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only